Analysts Anticipate Dicerna Pharmaceuticals Inc (DRNA) to Announce -$0.24 EPS

Share on StockTwits

Brokerages expect Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) to post earnings per share of ($0.24) for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Dicerna Pharmaceuticals’ earnings. The highest EPS estimate is ($0.13) and the lowest is ($0.28). Dicerna Pharmaceuticals posted earnings per share of ($0.92) during the same quarter last year, which indicates a positive year-over-year growth rate of 73.9%. The company is scheduled to report its next earnings report on Thursday, November 1st.

Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.26). The business had revenue of $1.55 million during the quarter, compared to analyst estimates of $1.79 million. Dicerna Pharmaceuticals had a negative net margin of 1,642.81% and a negative return on equity of 97.39%.

A number of equities analysts have recently commented on the stock. SunTrust Banks lifted their target price on shares of Dicerna Pharmaceuticals to $20.00 and gave the company a “buy” rating in a report on Thursday. HC Wainwright reaffirmed a “hold” rating and issued a $14.00 target price on shares of Dicerna Pharmaceuticals in a report on Tuesday, May 15th. Stifel Nicolaus lifted their price objective on shares of Dicerna Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday, August 9th. BidaskClub lowered shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 18th. Finally, ValuEngine lowered shares of Dicerna Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $15.54.

Shares of Dicerna Pharmaceuticals stock traded down $2.64 during trading on Friday, reaching $13.26. The company’s stock had a trading volume of 48,371 shares, compared to its average volume of 314,956. The stock has a market capitalization of $839.25 million, a price-to-earnings ratio of -3.93 and a beta of 2.43. Dicerna Pharmaceuticals has a fifty-two week low of $3.15 and a fifty-two week high of $17.50. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.40 and a quick ratio of 5.40.

In related news, Director Dennis Langer sold 14,531 shares of Dicerna Pharmaceuticals stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $16.00, for a total value of $232,496.00. Following the transaction, the director now directly owns 29,064 shares in the company, valued at approximately $465,024. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 19.85% of the company’s stock.

A number of large investors have recently bought and sold shares of DRNA. Millennium Management LLC grew its position in Dicerna Pharmaceuticals by 142.8% in the 4th quarter. Millennium Management LLC now owns 66,907 shares of the biopharmaceutical company’s stock valued at $604,000 after buying an additional 39,348 shares during the last quarter. Quantitative Systematic Strategies LLC purchased a new stake in shares of Dicerna Pharmaceuticals during the 1st quarter worth $113,000. Manchester Capital Management LLC purchased a new stake in shares of Dicerna Pharmaceuticals during the 1st quarter worth $180,000. Northern Trust Corp boosted its position in shares of Dicerna Pharmaceuticals by 63.7% during the 1st quarter. Northern Trust Corp now owns 59,384 shares of the biopharmaceutical company’s stock worth $568,000 after purchasing an additional 23,102 shares in the last quarter. Finally, BlackRock Inc. boosted its position in shares of Dicerna Pharmaceuticals by 136.5% during the 1st quarter. BlackRock Inc. now owns 277,493 shares of the biopharmaceutical company’s stock worth $2,652,000 after purchasing an additional 160,172 shares in the last quarter. Hedge funds and other institutional investors own 87.02% of the company’s stock.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.

Featured Article: Asset Allocation and Your Retirement

Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply